Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Health Secretary Vows Aid To India In Setting Up FDA Version (India)

This article was originally published in PharmAsia News

Executive Summary

U.S. Health and Human Services Secretary Michael Leavitt said during a visit to India that the United States plans to provide technical assistance to develop a Center for Food and Drug Administration in the country. Leavitt explained that the intention is to augment India's effort to develop and equip an FDA similar to that of the U.S. He said his counterpart, Union Health Minister Anbumani Ramadoss, indicated India wanted technical advice from the United States. Leavitt also said the U.S. is interested in having an FDA liaison office in India. (Click here for more

You may also be interested in...



Genomma Enjoys Strong Q2 Thanks To Big Gains in US

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Executives On The Move: New CEOs At Alentis Therapeutics, Melinta Therapeutics And NBE-Therapeutics

New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.

Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India

After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel